Her2 : un modèle de cible thérapeutique-Reference-Cited by-同舟云学术

Her2 : un modèle de cible thérapeutique

Published:2011-09 Issue:9 Volume:98 Page:1011-1017
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:fr
Short-container-title:Bulletin du Cancer

Author:

Marijon Hélène,André Fabrice

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference27 articles.

1. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling;Graus-Porta;EMBO J,1997

2. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells;Neve;Oncogene,2000

3. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy;Wen;Oncogene,2006

4. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene;Zhai;Cancer Res,1993

5. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines;Choudhury;Int J Cancer,2004

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TKIs in Renal Cell Carcinoma;Oncogenomics;2019

2. Radiothérapie mammaire locorégionale et traitement concomitant par trastuzumab;Bulletin du Cancer;2014-01

3. Identifying targets for the restoration and reactivation of BRM;Oncogene;2013-03-25

4. Le point de vue du clinicien : ciblage des kinases en pathologie mammaire;Annales de Pathologie;2011-11